About PPX


The question for this industry is no longer how to make it legal. It is how to compete and grow in newly legal markets. PPX was built for that second question.

PPX is a strategic pillar within Prohibition Partners — the organisation that has tracked, analysed and shaped the global cannabis industry for a decade.

Our clients don't just get campaigns. They get proprietary market intelligence, direct introductions to investors and operators, visibility through the world's largest B2B cannabis media network, and strategic guidance informed by regulatory insight across every major market.

We turn that platform into commercial outcomes: faster launches, smarter positioning, stronger networks, measurable growth.

What we deliver

  1. 01Strategy, positioning & market entryPositioning and market-entry decisions grounded in Prohibition Partners' proprietary data, led by PPX's senior advisory team.
  2. 02Compliant executionMessaging reviewed against current regulation before it ships. Companies that communicate effectively within the rules have an edge over those that can't.
  3. 03Introductions built on trustA curated, vetted network compresses timelines — trust built over a decade transfers directly into partnerships and revenue.

Leadership

Heidi Whitman, Managing Director, PPX

Heidi Whitman

Managing Director, PPX

Global strategic advisor · Co-Founder & Chairwoman, EmpowHer Cannabis Society e.V.

Heidi Whitman is an international strategic advisor specialising in cannabis, plant-based therapeutics and regulated wellness markets. With over a decade of experience across the UK, EU and global ecosystems, she focuses on governance, compliance, financial architecture and cross-border market entry for companies seeking sustainable, scalable growth.

She is the Co-Founder and Chairwoman of the EmpowHer Cannabis Society — a global network of women driving progress, inclusion and leadership across the cannabis and plant-based health industries, spanning 43+ countries and 1,000+ members.

Heidi is known for her “high functioning, not high” philosophy — precision dosing, product diversification and responsible frameworks that put patient outcomes and everyday functionality first. Her work bridges industry, policy and investment, supporting governments, operators and innovators in building compliant markets grounded in transparency and trust.

Start the conversation